Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 35Kidney Neoplasms 8Neoplasms 6Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Carcinoma, Hepatocellular 5Colorectal Neoplasms 4Recurrence 3Lung Neoplasms 3Glioblastoma 3Carcinoma 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Liver Neoplasms 2Endometrial Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Adenoid Cystic 2cT2a N0NxM0 Renal Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Solitary Fibrous Tumors 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Relapsed Pediatric Solid Tumor 1Radiation Therapy 1

Interventions

Cyclophosphamide 116fludarabine phosphate 101Busulfan 83Tacrolimus 75fludarabine 73Mycophenolic Acid 71Whole-Body Irradiation 65Peripheral Blood Stem Cell Transplantation 59Antilymphocyte Serum 58Cyclosporine 53Azacitidine 53Melphalan 50Cytarabine 47Filgrastim 43Methotrexate 41Granulocyte Colony-Stimulating Factor 34Decitabine 33Radiotherapy 28Thiotepa 27Cord Blood Stem Cell Transplantation 27thymoglobulin 26Stem Cell Transplantation 26Clofarabine 22Methylprednisolone 20Sirolimus 19Alemtuzumab 16venetoclax 15Specimen Handling 14sargramostim 13Etoposide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic Syndromes × Axitinib × Clear all
NCT00071006 2012-06-08

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Pfizer

Phase 2 Completed
12 enrolled 5 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡